A survey on the current status of hepatitis B patients conducted by the Chinese Medical Association, an authoritative professional academic institution in China, among more than 400 hepatitis B patients in six cities nationwide, found that only 19% of slow hepatitis B patients in China are receiving the correct treatment, and up to 73% of the subjects are using unregulated treatment methods. So what is the best way to treat hepatitis B at the moment? Antiviral therapy is the key to the treatment of slow hepatitis B: The treatment of slow hepatitis B mainly includes antiviral, anti-inflammatory and hepatoprotective, anti-fibrotic and symptomatic therapy, of which antiviral therapy is the key, and as long as there are indications and conditions allow, standardized antiviral therapy should be administered. A large number of studies have confirmed that antiviral therapy is the key to slowing down the progress of hepatitis B. Standardized antiviral therapy can significantly reduce the incidence of cirrhosis and liver cancer. Other drugs such as hepatoprotective drugs should only be used as adjuvant treatment drugs. Standardized antiviral therapy should be started at the right time: the timing of antiviral therapy is closely related to the patient’s immune status, as judged by liver function, viral indicators, liver puncture biopsy results, ultrasonography and other ancillary tests. Chronic hepatitis B can be divided into immune tolerance phase, immune clearance phase, inactive or low (non)-replication phase and reactivation phase, of which the immune clearance phase is the right time for antiviral therapy. During the immune clearance phase, the body’s immune system begins to recognize and remove the virus from the liver cells, and the struggle between the two results in a hepatitis attack that manifests as abnormal liver function such as elevated transaminases. The right time to start antiviral therapy is usually when a patient’s transaminases are elevated to more than two times the upper limit of normal. Understand the characteristics of antiviral therapy drugs and follow medical advice based on your own situation: Currently, antiviral drugs are divided into two categories: interferon drugs and nucleoside drugs. Interferons are characterized by a relatively fixed course of treatment, a high rate of e antigen serological conversion and surface antigen clearance, and once treatment is effective, the efficacy can be maintained for a long time after discontinuation; nucleosides are characterized by rapid inhibition of viral replication, rapid virological conversion and a high rate of conversion, but these drugs usually require long-term treatment, and the course of treatment is not fixed. The current view is that interferon-based therapy can be tried first in patients who expect a short course of treatment and are expected to be able to stop taking the drug for a long time, especially in young patients who do not have contraindications to interferon. For older patients who are able to receive long-term treatment, nucleoside analogs are also good choices, although there is a risk of resistance to long-term treatment with these drugs, and it is best to choose drugs with a lower risk of resistance, such as entecavir and tenofovir, if conditions permit. In conclusion, patients must visit a regular specialist hospital or department in a timely manner and undergo standardized treatment. As each patient’s situation is very different, doctors need to develop a treatment plan based on the patient’s specific situation.